US2012142744A1PendingUtilityA1
Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
Est. expiryJun 20, 2022(expired)· nominal 20-yr term from priority
Inventors:Morten Weidner
A61P 5/40A61P 43/00A61P 39/02A61P 7/06A61P 37/02A61P 37/06A61P 37/08A61P 25/02A61P 31/16A61P 3/10A61P 31/10A61P 33/00A61P 27/16A61P 29/00A61P 31/14A61P 31/04A61P 31/00A61P 35/00A61P 31/12A61P 31/22A61P 31/08A61P 17/06A61K 8/4926A61P 17/14A61P 17/00A61P 17/08A61P 19/10A61P 17/04A61P 11/02A61P 17/10A61K 8/37A61P 21/04A61Q 19/007A61K 31/44A61P 17/16A61P 1/16A61P 13/12A61P 11/06A61Q 19/00A61P 1/04A61K 2800/75A61P 11/00A61P 19/02A61K 31/455A61K 31/765A61P 19/06A61Q 17/005Y02A50/30
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel combinations of fatty acid derivatives and pyridine carboxy derivatives, including fatty acid esters with glycerol and 3-carboxy pyridine derivates such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed herein.
Claims
exact text as granted — not AI-modified1 - 62 . (canceled)
63 . A method for the treatment of a disease associated with hypersensitivity and/or inflammatory reactions, said method comprising the administration of
i) glyceryl monocaprylate or an alkali metal salt thereof and ii) niacinamide or a salt thereof,
wherein said disease is selected from the group consisting of hypersensitivity skin disease, pruritus, urticaria, atopic eczema, contact dermatitis, seborrhoeic dermatitis, acne, rosacea, alopecia, vitiligo, and psoriasis.
64 . The method according to claim 63 , wherein said disease is seborrhoeic dermatitis.
65 . The method according to claim 63 , wherein the component (i) is racemic, enantiomerically enriched or enantiomerically pure 1-glyceryl-monocaprylate.
66 . The method according to claim 63 , wherein the component (ii) is niacinamide.
67 . The method according to claim 63 , wherein said combination further comprises one or more therapeutically active agents.
68 . The method according to claim 63 , wherein the combination is formulated for oral, topical, transdermal, or parenteral administration.
69 . The method according to claim 68 , wherein the combination is formulated for topical administration.
70 . The method according to claim 63 , wherein the component (i) and the component (ii) are present in a molar ratio of between about 1:3 to 1:16.
71 . The method according to claim 70 , wherein the component (i) and the component (ii) are present in a molar ratio of about 1:14 or about 2:7.
72 . The method according to claim 65 , wherein the component (ii) is niacinamide.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.